Provided By GlobeNewswire
Last update: Dec 20, 2023
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).
NASDAQ:PMN (4/30/2025, 10:09:24 AM)
0.575
-0.01 (-1.37%)
Find more stocks in the Stock Screener